All drug products undergo sterility testing to comply with Good Manufacturing Practices (GMP). Parenteral drug products go through especially rigorous testing to ensure sterility and safety, otherwise risking contamination, which can lead to expensive reputation-damaging recalls and illness. Until recently, current testing methods have fallen short for products intended for immediate use. Rapid sterility testing provides a solution, offering an incubation period of five days or less. This rapid turnaround suits today’s tailored medicines and allows companies to get their products to market faster.

Your takeaways from this white paper:

  1. Increased reliability assurance for sterility testing
  2. Time saving (Short TAT)
  3. Cost savings (less product required)